Develops and manufactures synthetic crystals for various applications. Produces optical materials, components, and coatings. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.6× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 35% below its peak. The market has trimmed its expectations for the company.
Sales run at $43.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 23 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $392K against $43.7M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.